Published online Nov 26, 2019. doi: 10.12998/wjcc.v7.i22.3881
Peer-review started: July 23, 2019
First decision: September 9, 2019
Revised: September 17, 2019
Accepted: October 5, 2019
Article in press: October 5, 2019
Published online: November 26, 2019
Processing time: 128 Days and 17.7 Hours
Pseudomyxoma peritonei (PMP) is a rare benign, but progressive, disease according to myxoma histopathology. Surgical resection is the preferred and most effective treatment, but the outcomes are often unsatisfactory.
A 63-year-old Chinese woman with PMP received apatinib at a daily dose of 0.5 mg for 15 d per cycle and at a daily dose of 0.4 mg to date for recurrent abdominal distension after surgical treatment and hyperthermic intraperitoneal chemotherapy. During the follow-up period, apatinib was the maintenance treatment with a progression-free period of 10 mo and the toxicity of apatinib was controllable and tolerable. Unfortunately, recurrence occurred 10 mo after administration. After two operations, the patient gave up treatment at the 18th mo and eventually died of intestinal obstruction and multiple organ failure.
Apatinib may be an option for recurrent PMP after surgical treatment, but this conclusion remains to be confirmed.
Core tip: The preferred treatment for pseudomyxoma peritonei (PMP) is surgery, but it is easy to relapse after surgery. There is currently no good treatment for patients with postoperative recurrence. In this work, a PMP patient received apatinib for recurrent abdominal distension after surgical treatment and hyperthermic intraperitoneal chemotherapy. After treatment with apatinib, the recurrence time was significantly prolonged. Apatinib, a small-molecule oral inhibitor with anti-angiogenic function, may be an option for recurrent PMP after surgical treatment.